14 results on '"Hany E"'
Search Results
2. Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired
- Author
-
Marei, Hany E., Hasan, Anwarul, Pozzoli, Giacomo, and Cenciarelli, Carlo
- Published
- 2023
- Full Text
- View/download PDF
3. Potential of antibody–drug conjugates (ADCs) for cancer therapy
- Author
-
Marei, Hany E., Cenciarelli, Carlo, and Hasan, Anwarul
- Published
- 2022
- Full Text
- View/download PDF
4. Multimodal targeting of glioma with functionalized nanoparticles
- Author
-
Marei, Hany E.
- Published
- 2022
- Full Text
- View/download PDF
5. Exome sequencing of glioblastoma-derived cancer stem cells reveals rare clinically relevant frameshift deletion in MLLT1 gene
- Author
-
Marei, Hany E., Althani, Asmaa, Afifi, Nahla, Hasan, Anwarul, Caceci, Thomas, Felsani, Armando, Tringali, Giuseppe, Cifola, Ingrid, Pozzoli, Giacomo, and Cenciarelli, Carlo
- Published
- 2022
- Full Text
- View/download PDF
6. p53 signaling in cancer progression and therapy
- Author
-
Marei, Hany E., Althani, Asmaa, Afifi, Nahla, Hasan, Anwarul, Caceci, Thomas, Pozzoli, Giacomo, Morrione, Andrea, Giordano, Antonio, and Cenciarelli, Carlo
- Published
- 2021
- Full Text
- View/download PDF
7. Erratum to: Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA)
- Author
-
Kuo Ching Yuan, Sujith J Chandy, Katia Iskandar, Michael McFarlane, Nathalie Guessennd, M. Bala, Timothy M. Rawson, Francesco M. Labricciosa, Sandro Rizoli, Stephen M. Brecher, Alain Chichom-Mefire, Richard Ofori-Asenso, Rao R. Ivatury, Miguel Sanchez-Garcia, Ngo Tat Trung, Carlos Augusto Gomes, Angel Dillip, Yunfeng Cui, Yousheng Li, Antonio Corcione, Tonny Loho, F. Corcione, Vishalkumar G Shelat, Federico Coccolini, Helen Giamarellou, W. R. Heizmann, Richard R. Watkins, Zaza Demetrashvili, Asma Althani, Iain J. Abbott, Andreas Hecker, Addison K. May, Adrián Camacho-Ortiz, Wagih Ghnnam, Sydney Malama, Kenneth Y.Y. Kok, Jonathan Tilsed, Shamshul Ansari, Garima Kapoor, Young R. Lee, B. Sakakushev, A R K Adesunkanmi, Fausto Catena, Kjetil Søreide, Andrew W. Kirkpatrick, Rifat Latifi, Daniel Curcio, Marc Leone, Norio Sato, Arda Isik, Robert G. Sawyer, Gereltuya Dorj, Mouaqit Ouadii, F. A. Moore, Miran Rems, Jason A. Roberts, Ravinder S. Vohra, Fikri M. Abu-Zidan, András Vereczkei, Zsolt J. Balogh, Georgios Gkiokas, Sara Al-Dahir, Walter L. Biffl, Raul Coimbra, Sonja Hansen, Mainul Haque, Kenji Inaba, Ferdinando Agresta, Jean-Ralph Zahar, Miguel Caínzos, Ari Leppäniemi, Pierre-François Laterre, S. Di Saverio, Jean-François Timsit, Vladimir Khokha, Gabriele Sganga, Luca Ansaloni, Brian J. Wright, Jean Louis Vincent, Agron Dogjani, Jan Ulrych, Reinhold Kafka-Ritsch, Paula Ferrada, Sanjay Marwah, Rashid Ansumana, Swati Dhingra, Lewis J. Kaplan, Warren Lowman, Aneel Bhangu, Matthew C Knox, Ionut Negoi, Yonghong Xiao, Gabriel Trueba, H. A. Segovia Lohse, Claudio Rocha, Waldemar Uhl, Joseph R Fitchett, Gustavo Pereira Fraga, Michael P. Doyle, Jae G. Lee, Goran Augustin, Valery N. Egiev, G. A. Pereira Júnior, Jakub Kenig, Ashwani Kumar, Abdelkarim H. Omari, Peter K. Kim, Oussema Baraket, Suk-Kyung Hong, Stephen Y. Liang, Ernest E. Moore, Torsten Herzog, Mutasim M. Elmangory, Victor Y. Kong, Hervé Dupont, John E. Mazuski, H. van Goor, Pierluigi Viale, Kelly A. Cairns, Guntars Pupelis, Martin G. Kees, Philippe Montravers, Christian Eckmann, R. V. Maier, Yoram Kluger, Marja A. Boermeester, Carl Erik Nord, Ronald Kiguba, Etienne Ruppé, Harumi Gomi, Hany E. Marei, Ewen A. Griffiths, J. J. De Waele, Mushira Enani, Ignacio Martin-Loeches, Boonying Siribumrungwong, B. De Simone, Rodolfo Soto, Caroline Colijn, Samir Delibegovic, Stephanie Goldberg, Marcelo A. Beltrán, Rita Maria Melotti, Matteo Bassetti, Adrien Hodonou, Marc Maegele, Sanoop K. Zachariah, Jill R. Cherry-Bukowiec, Dominik Mertz, Claudio Viscoli, Diego Piazza, Massimo Sartelli, O.R. Buyne, Manuel Guzman-Blanco, Majdi N. Al-Hasan, Peep Talving, Michael Bernhard, Imtiaz Wani, Renato Bessa Melo, I. Di Carlo, Tanya L. Zakrison, Dieter G. Weber, Soumitra R. Eachempati, Carlos A. Ordoñez, Amos Massele, Kaoru Koike, Aleksandar Karamarkovic, Adrian Brink, Brad Spellberg, Maurizio Labbate, David P. Nicolau, Jose J. Diaz, A. Che Jusoh, and Engineering & Physical Science Research Council (EPSRC)
- Subjects
medicine.medical_specialty ,International Cooperation ,lcsh:Surgery ,Peritonitis ,Microbial Sensitivity Tests ,Tigecycline ,030230 surgery ,medicine.disease_cause ,Emerging and Re-emerging Infectious Diseases ,03 medical and health sciences ,0302 clinical medicine ,Antibiotic resistance ,Anti-Infective Agents ,medicine ,Humans ,Agora ,Intensive care medicine ,computer.programming_language ,Science & Technology ,business.industry ,Abdominal Infection ,lcsh:Medical emergencies. Critical care. Intensive care. First aid ,Drug Resistance, Microbial ,030208 emergency & critical care medicine ,lcsh:RD1-811 ,lcsh:RC86-88.9 ,Prognosis ,medicine.disease ,Antimicrobial ,Methicillin-resistant Staphylococcus aureus ,Spelling ,3. Good health ,Emergency Medicine ,Intraabdominal Infections ,Surgery ,Artificial intelligence ,Erratum ,business ,computer ,Life Sciences & Biomedicine ,medicine.drug - Abstract
Intra-abdominal infections (IAI) are an important cause of morbidity and are frequently associated with poor prognosis, particularly in high-risk patients. The cornerstones in the management of complicated IAIs are timely effective source control with appropriate antimicrobial therapy. Empiric antimicrobial therapy is important in the management of intra-abdominal infections and must be broad enough to cover all likely organisms because inappropriate initial antimicrobial therapy is associated with poor patient outcomes and the development of bacterial resistance. The overuse of antimicrobials is widely accepted as a major driver of some emerging infections (such as C. difficile), the selection of resistant pathogens in individual patients, and for the continued development of antimicrobial resistance globally. The growing emergence of multi-drug resistant organisms and the limited development of new agents available to counteract them have caused an impending crisis with alarming implications, especially with regards to Gram-negative bacteria. An international task force from 79 different countries has joined this project by sharing a document on the rational use of antimicrobials for patients with IAIs. The project has been termed AGORA (Antimicrobials: A Global Alliance for Optimizing their Rational Use in Intra-Abdominal Infections). The authors hope that AGORA, involving many of the world's leading experts, can actively raise awareness in health workers and can improve prescribing behavior in treating IAIs.
- Published
- 2017
8. Antimicrobials
- Author
-
University of Helsinki, II kirurgian klinikka, Sartelli, Massimo, Weber, Dieter G., Ruppe, Etienne, Bassetti, Matteo, Wright, Brian J., Ansaloni, Luca, Catena, Fausto, Coccolini, Federico, Abu-Zidan, Fikri M., Coimbra, Raul, Moore, Ernest E., Moore, Frederick A., Maier, Ronald V., De Waele, Jan J., Kirkpatrick, Andrew W., Griffiths, Ewen A., Eckmann, Christian, Brink, Adrian J., Mazuski, John E., May, Addison K., Sawyer, Rob G., Mertz, Dominik, Montravers, Philippe, Kumar, Anand, Roberts, Jason A., Vincent, Jean-Louis, Watkins, Richard R., Lowman, Warren, Spellberg, Brad, Abbott, Iain J., Adesunkanmi, Abdulrashid Kayode, Al-Dahir, Sara, Al-Hasan, Majdi N., Agresta, Ferdinando, Althani, Asma A., Ansari, Shamshul, Ansumana, Rashid, Augustin, Goran, Bala, Miklosh, Balogh, Zsolt J., Baraket, Oussama, Bhangu, Aneel, Beltran, Marcelo A., Bernhard, Michael, Biffl, Walter L., Boermeester, Marja A., Brecher, Stephen M., Cherry-Bukowiec, Jill R., Buyne, Otmar R., Cainzos, Miguel A., Cairns, Kelly A., Camacho-Ortiz, Adrian, Chandy, Sujith J., Jusoh, Asri Che, Chichom-Mefire, Alain, Colijn, Caroline, Corcione, Francesco, Cui, Yunfeng, Curcio, Daniel, Delibegovic, Samir, Demetrashvili, Zaza, De Simone, Belinda, Dhingra, Sameer, Diaz, Jose J., Di Carlo, Isidoro, Dillip, Angel, Di Saverio, Salomone, Doyle, Michael P., Dorj, Gereltuya, Dogjani, Agron, Dupont, Herve, Eachempati, Soumitra R., Enani, Mushira Abdulaziz, Egiev, Valery N., Elmangory, Mutasim M., Ferrada, Paula, Fitchett, Joseph R., Fraga, Gustavo P., Guessennd, Nathalie, Giamarellou, Helen, Ghnnam, Wagih, Gkiokas, George, Goldberg, Staphanie R., Gomes, Carlos Augusto, Gomi, Harumi, Guzman-Blanco, Manuel, Haque, Mainul, Hansen, Sonja, Hecker, Andreas, Heizmann, Wolfgang R., Herzog, Torsten, Hodonou, Adrien Montcho, Hong, Suk-Kyung, Kafka-Ritsch, Reinhold, Kaplan, Lewis J., Kapoor, Garima, Karamarkovic, Aleksandar, Kees, Martin G., Kenig, Jakub, Kiguba, Ronald, Kim, Peter K., Kluger, Yoram, Khokha, Vladimir, Koike, Kaoru, Kok, Kenneth Y. Y., Kong, Victory, Knox, Matthew C., Inaba, Kenji, Isik, Arda, Iskandar, Katia, Ivatury, Rao R., Labbate, Maurizio, Labricciosa, Francesco M., Laterre, Pierre-Francois, Latifi, Rifat, Lee, Jae Gil, Lee, Young Ran, Leone, Marc, Leppäniemi, Ari, Li, Yousheng, Liang, Stephen Y., Loho, Tonny, Maegele, Marc, Malama, Sydney, Marei, Hany E., Martin-Loeches, Ignacio, Marwah, Sanjay, Massele, Amos, McFarlane, Michael, Melo, Renato Bessa, Negoi, Ionut, Nicolau, David P., Nord, Carl Erik, Ofori-Asenso, Richard, Omari, AbdelKarim H., Ordonez, Carlos A., Ouadii, Mouaqit, Pereira Junior, Gerson Alves, Piazza, Diego, Pupelis, Guntars, Rawson, Timothy Miles, Rems, Miran, Rizoli, Sandro, Rocha, Claudio, Sakakhushev, Boris, Sanchez-Garcia, Miguel, Sato, Norio, Lohse, Helmut A. Segovia, Sganga, Gabriele, Siribumrungwong, Boonying, Shelat, Vishal G., Soreide, Kjetil, Soto, Rodolfo, Talving, Peep, Tilsed, Jonathan V., Timsit, Jean-Francois, Trueba, Gabriel, Trung, Ngo Tat, Ulrych, Jan, van Goor, Harry, Vereczkei, Andras, Vohra, Ravinder S., Wani, Imtiaz, Uhl, Waldemar, Xiao, Yonghong, Yuan, Kuo-Ching, Zachariah, Sanoop K., Zahar, Jean-Ralph, Zakrison, Tanya L., Corcione, Antonio, Melotti, Rita M., Viscoli, Claudio, Viale, Perluigi, University of Helsinki, II kirurgian klinikka, Sartelli, Massimo, Weber, Dieter G., Ruppe, Etienne, Bassetti, Matteo, Wright, Brian J., Ansaloni, Luca, Catena, Fausto, Coccolini, Federico, Abu-Zidan, Fikri M., Coimbra, Raul, Moore, Ernest E., Moore, Frederick A., Maier, Ronald V., De Waele, Jan J., Kirkpatrick, Andrew W., Griffiths, Ewen A., Eckmann, Christian, Brink, Adrian J., Mazuski, John E., May, Addison K., Sawyer, Rob G., Mertz, Dominik, Montravers, Philippe, Kumar, Anand, Roberts, Jason A., Vincent, Jean-Louis, Watkins, Richard R., Lowman, Warren, Spellberg, Brad, Abbott, Iain J., Adesunkanmi, Abdulrashid Kayode, Al-Dahir, Sara, Al-Hasan, Majdi N., Agresta, Ferdinando, Althani, Asma A., Ansari, Shamshul, Ansumana, Rashid, Augustin, Goran, Bala, Miklosh, Balogh, Zsolt J., Baraket, Oussama, Bhangu, Aneel, Beltran, Marcelo A., Bernhard, Michael, Biffl, Walter L., Boermeester, Marja A., Brecher, Stephen M., Cherry-Bukowiec, Jill R., Buyne, Otmar R., Cainzos, Miguel A., Cairns, Kelly A., Camacho-Ortiz, Adrian, Chandy, Sujith J., Jusoh, Asri Che, Chichom-Mefire, Alain, Colijn, Caroline, Corcione, Francesco, Cui, Yunfeng, Curcio, Daniel, Delibegovic, Samir, Demetrashvili, Zaza, De Simone, Belinda, Dhingra, Sameer, Diaz, Jose J., Di Carlo, Isidoro, Dillip, Angel, Di Saverio, Salomone, Doyle, Michael P., Dorj, Gereltuya, Dogjani, Agron, Dupont, Herve, Eachempati, Soumitra R., Enani, Mushira Abdulaziz, Egiev, Valery N., Elmangory, Mutasim M., Ferrada, Paula, Fitchett, Joseph R., Fraga, Gustavo P., Guessennd, Nathalie, Giamarellou, Helen, Ghnnam, Wagih, Gkiokas, George, Goldberg, Staphanie R., Gomes, Carlos Augusto, Gomi, Harumi, Guzman-Blanco, Manuel, Haque, Mainul, Hansen, Sonja, Hecker, Andreas, Heizmann, Wolfgang R., Herzog, Torsten, Hodonou, Adrien Montcho, Hong, Suk-Kyung, Kafka-Ritsch, Reinhold, Kaplan, Lewis J., Kapoor, Garima, Karamarkovic, Aleksandar, Kees, Martin G., Kenig, Jakub, Kiguba, Ronald, Kim, Peter K., Kluger, Yoram, Khokha, Vladimir, Koike, Kaoru, Kok, Kenneth Y. Y., Kong, Victory, Knox, Matthew C., Inaba, Kenji, Isik, Arda, Iskandar, Katia, Ivatury, Rao R., Labbate, Maurizio, Labricciosa, Francesco M., Laterre, Pierre-Francois, Latifi, Rifat, Lee, Jae Gil, Lee, Young Ran, Leone, Marc, Leppäniemi, Ari, Li, Yousheng, Liang, Stephen Y., Loho, Tonny, Maegele, Marc, Malama, Sydney, Marei, Hany E., Martin-Loeches, Ignacio, Marwah, Sanjay, Massele, Amos, McFarlane, Michael, Melo, Renato Bessa, Negoi, Ionut, Nicolau, David P., Nord, Carl Erik, Ofori-Asenso, Richard, Omari, AbdelKarim H., Ordonez, Carlos A., Ouadii, Mouaqit, Pereira Junior, Gerson Alves, Piazza, Diego, Pupelis, Guntars, Rawson, Timothy Miles, Rems, Miran, Rizoli, Sandro, Rocha, Claudio, Sakakhushev, Boris, Sanchez-Garcia, Miguel, Sato, Norio, Lohse, Helmut A. Segovia, Sganga, Gabriele, Siribumrungwong, Boonying, Shelat, Vishal G., Soreide, Kjetil, Soto, Rodolfo, Talving, Peep, Tilsed, Jonathan V., Timsit, Jean-Francois, Trueba, Gabriel, Trung, Ngo Tat, Ulrych, Jan, van Goor, Harry, Vereczkei, Andras, Vohra, Ravinder S., Wani, Imtiaz, Uhl, Waldemar, Xiao, Yonghong, Yuan, Kuo-Ching, Zachariah, Sanoop K., Zahar, Jean-Ralph, Zakrison, Tanya L., Corcione, Antonio, Melotti, Rita M., Viscoli, Claudio, and Viale, Perluigi
- Abstract
Intra-abdominal infections (IAI) are an important cause of morbidity and are frequently associated with poor prognosis, particularly in high-risk patients. The cornerstones in the management of complicated IAIs are timely effective source control with appropriate antimicrobial therapy. Empiric antimicrobial therapy is important in the management of intra-abdominal infections and must be broad enough to cover all likely organisms because inappropriate initial antimicrobial therapy is associated with poor patient outcomes and the development of bacterial resistance. The overuse of antimicrobials is widely accepted as a major driver of some emerging infections (such as C. difficile), the selection of resistant pathogens in individual patients, and for the continued development of antimicrobial resistance globally. The growing emergence of multi-drug resistant organisms and the limited development of new agents available to counteract them have caused an impending crisis with alarming implications, especially with regards to Gram-negative bacteria. An international task force from 79 different countries has joined this project by sharing a document on the rational use of antimicrobials for patients with IAIs. The project has been termed AGORA (Antimicrobials: A Global Alliance for Optimizing their Rational Use in Intra-Abdominal Infections). The authors hope that AGORA, involving many of the world's leading experts, can actively raise awareness in health workers and can improve prescribing behavior in treating IAIs.
- Published
- 2016
9. Association of IL-10 gene polymorphisms and susceptibility to Juvenile Idiopathic Arthritis in Egyptian children and adolescents: a case-control study.
- Author
-
Fathy, Manar M., Elsaadany, Hosam F., Ali, Yasser F., Farghaly, Mohsen A. A., Hamed, Mohammed E., Ibrahim, Hany E., Noah, Maha A., Allah, Mayy A. N., Elashkar, Shaimaa S. A., Abdelsalam, Nasser I., Abdelrahman, Hind M., Ahmed, Ahmed R., Anany, Heba G., Ismail, Sanaa M., Ibrahim, Boshra R., Al Azizi, Nashwa M., Gawish, Heba H., Al-Akad, Ghada M., Nabil, Rehab M., and Fahmy, Dalia S.
- Subjects
GENETICS of disease susceptibility ,ALLELES ,JUVENILE idiopathic arthritis ,CHRONIC diseases ,CONFIDENCE intervals ,ENZYME-linked immunosorbent assay ,GENETIC polymorphisms ,INTERLEUKINS ,POLYMERASE chain reaction ,PROBABILITY theory ,CASE-control method ,DESCRIPTIVE statistics ,ODDS ratio ,GENOTYPES ,CHILDREN ,GENETICS ,DISEASE risk factors - Abstract
Background: Juvenile Idiopathic Arthritis (JIA) is the most common chronic arthritis in children worldwide. Among anti-inflammatory cytokines, interleukin-10 (IL-10) is a key immunosuppressive cytokine involved in the pathogenesis of JIA. To date, only a few studies concerned the association of interleukin-10 gene polymorphisms with JIA. In this study, we aimed to investigate 3 cytokine single-nucleotide polymorphisms situated at positions -1082(G/A), -819(C/T), and -592(C/A) in the promoter region of the IL-10 gene to determine whether this polymorphism could be a marker of susceptibility to JIA in Egyptian children and adolescents. We also measured the serum level of IL-10 to assess its relation to such polymorphism. Methods: This was a case-control study included 100 patients diagnosed with JIA, and matched with age, gender, ethnicity 100 healthy control subjects. Interleukin-10 -1082(G/A), -819(C/T), and -592(C/A) polymorphisms were genotyped by amplification refractory mutation system- polymerase chain reaction (ARMS)-PCR methodology, while the serum IL10 levels were measured by ELISA method. Results: Compared to the controls subjects, the frequency of IL-10- AA genotype and A allele at the -1082 position were overrepresented in patients with JIA (OR = 2.7; 95% CI: 1.1-6.4 for the AA genotype; P <0.05 and OR: 1.5; 95% CI: 1.03-2.3 for the A allele; P <0.05 respectively). On the other hand, no significant differences were found between the 2 groups in the genotype or allele frequencies for the -819 and -592 positions. Of note, we found a significant positive association between the IL-10 (-1082) AA genotype and susceptibility to polyarticular JIA (OR: 4.3; 95% CI: 1.5-12.7; P <0.01). We observed that patients with the IL-10 (-1082) AA genotype had significantly lower serum IL-10 levels (2.3 ± 0.9 pg/ml) compared to those with AG genotype (7.6 ± 1.5 pg/ml) and GG genotype (9.5 ± 1.2 pg/ml); P < 0.01, respectively. Conclusion: We demonstrate for the first time, to the best of our knowledge, that the presence of an A allele or AA gene variant at the -1082 position of the promoter region of the interleukin-10 gene may constitute risk factors for developing JIA in Egyptian children and adolescents. Moreover, we observed a significant positive association between the IL10 -1082 AA gene variant and susceptibility to polyarticular JIA. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
10. Comparison of adipose tissue- and bone marrow- derived mesenchymal stem cells for alleviating doxorubicin-induced cardiac dysfunction in diabetic rats.
- Author
-
Ammar, Hania Ibrahim, Sequiera, Glen Lester, Nashed, Mira B., Ammar, Rasha I., Gabr, Hala M., Elsayed, Hany E., Sareen, Niketa, Abu-El Rub, Ejlal, Zickri, Maha B., and Dhingra, Sanjiv
- Subjects
BONE marrow cells ,MESENCHYMAL stem cells ,ADIPOSE tissues ,COMPARATIVE studies ,DOXORUBICIN ,HEART abnormalities ,LABORATORY rats - Abstract
Introduction: Doxorubicin (DOX) is a well-known anticancer drug. However its clinical use has been limited due to cardiotoxic effects. One of the major concerns with DOX therapy is its toxicity in patients who are frail, particularly diabetics. Several studies suggest that mesenchymal stem cells (MSCs) have the potential to restore cardiac function after DOX-induced injury. However, limited data are available on the effects of MSC therapy on DOX-induced cardiac dysfunction in diabetics. Our objective was to test the efficacy of bone marrow-derived (BM-MSCs) and adipose-derived MSCs (AT-MSCs) from age-matched humans in a non-immune compromised rat model. Methods: Diabetes mellitus was induced in rats by streptozotocin injection (STZ, 65 mg/kg b.w, i.p.). Diabetic rats were treated with DOX (doxorubicin hydrochloride, 2.5 mg/kg b.w, i.p) 3 times/wk for 2 weeks (DOX group); or with DOX+ GFP labelled BM-MSCs (2x106cells, i.v.) or with DOX + GFP labelled AT-MSCs (2x106cells, i.v.). Echocardiography and Langendorff perfusion analyses were carried out to determine the heart function. Immunostaining and western blot analysis of the heart tissue was carried out for CD31 and to assess inflammation and fibrosis. Statistical analysis was carried out using SPSS and data are expressed as mean ± SD. Results: Glucose levels in the STZ treated groups were significantly greater than control group. After 4 weeks of intravenous injection, the presence of injected MSCs in the heart was confirmed through fluorescent microscopy and real time PCR for ALU transcripts. Both BM-MSCs and AT-MSCs injection prevented DOX-induced deterioration of %FS, LVDP, dp/dt max and rate pressure product. Staining for CD31 showed a significant increase in the number of capillaries in BM-MSCs and AT-MSCs treated animals in comparison to DOX treated group. Assessment of the inflammation and fibrosis revealed a marked reduction in the DOX-induced increase in immune cell infiltration, collagen deposition and aSMA in the BM-MSCs and AT-MSCs groups. Conclusions: In conclusion BM-MSCs and AT-MSCs were equally effective in mitigating DOX-induced cardiac damage by promoting angiogenesis, decreasing the infiltration of immune cells and collagen deposition. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
11. PDGF receptor alpha inhibition induces apoptosis in glioblastoma cancer stem cells refractory to anti-Notch and anti-EGFR treatment.
- Author
-
Cenciarelli, Carlo, Marei, Hany E. S., Zonfrillo, Manuela, Pierimarchi, Pasquale, Paldino, Emanuela, Casalbore, Patrizia, Felsani, Armando, Vescovi, Angelo Luigi, Maira, Giulio, and Mangiola, Annunziato
- Subjects
- *
PLATELET-derived growth factor receptors , *GLIOBLASTOMA multiforme , *CANCER stem cells , *APOPTOSIS , *EPIDERMAL growth factor receptors , *GENE expression , *GENETICS - Abstract
Background: Cancer stem cells (CSC) represent a rare fraction of cancer cells characterized by resistance to chemotherapy and radiation, therefore nowadays there is great need to develop new targeted therapies for brain tumors and our study aim to target pivotal transmembrane receptors such as Notch, EGFR and PDGFR, which are already under investigation in clinical trials setting for the treatment of Glioblastoma Multiforme (GBM). Methods: MTS assay was performed to evaluate cells response to pharmacological treatments. Quantitative RT-PCR and Western blots were performed to state the expression of Notch1, EGFR and PDGFRα/β and the biological effects exerted by either single or combined targeted therapy in GBM CSC. GBM CSC invasive ability was tested in vitro in absence or presence of Notch and/or EGFR signaling inhibitors. Results: In this study, we investigated gene expression and function of Notch1, EGFR and PDGFR to determine their role among GBM tumor core- (c-CSC) vs. peritumor tissue derived cancer stem cells (p-CSC) of six cases of GBM. Notch inhibition significantly impaired cell growth of c-CSC compared to p-CSC pools, with no effects observed in cell cycle distribution, apoptosis and cell invasion assays. Instead, anti-EGFR therapy induced cell cycle arrest, sometimes associated with apoptosis and reduction of cell invasiveness in GBM CSC. In two cases, c-CSC pools were more sensitive to simultaneous anti-Notch and anti-EGFR treatment than either therapy alone compared to p-CSC, which were mostly resistant to treatment. We reported the overexpression of PDGFRα and its up-regulation following anti-EGFR therapy in GBM p-CSC compared to c-CSC. RNA interference of PDGFRα significantly reduced cell proliferation rate of p-CSC, while its pharmacological inhibition with Crenolanib impaired survival of both CSC pools, whose effects in combination with EGFR inhibition were maximized. Conclusions: We have used different drugs combination to identify the more effective therapeutic targets for GBM CSC, particularly against GBM peritumor tissue-derived CSC, which are mostly resistant to treatments. Overall, our results provide the rationale for simultaneous targeting of EGFR and PDGFR, which would be beneficial in the treatment of GBM. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
12. Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA)
- Author
-
Sartelli, Massimo, Weber, Dieter G., Ruppé, Etienne, Bassetti, Matteo, Wright, Brian J., Ansaloni, Luca, Catena, Fausto, Coccolini, Federico, Abu-Zidan, Fikri M., Coimbra, Raul, Moore, Ernest E., Moore, Frederick A., Maier, Ronald V., De Waele, Jan J., Kirkpatrick, Andrew W., Griffiths, Ewen A., Eckmann, Christian, Brink, Adrian J., Mazuski, John E., May, Addison K., Sawyer, Rob G., Mertz, Dominik, Montravers, Philippe, Kumar, Anand, Roberts, Jason A., Vincent, Jean-Louis, Watkins, Richard R., Lowman, Warren, Spellberg, Brad, Abbott, Iain J., Adesunkanmi, Abdulrashid Kayode, Al-Dahir, Sara, Al-Hasan, Majdi N., Agresta, Ferdinando, Althani, Asma A., Ansari, Shamshul, Ansumana, Rashid, Augustin, Goran, Bala, Miklosh, Balogh, Zsolt J., Baraket, Oussama, Bhangu, Aneel, Beltrán, Marcelo A., Bernhard, Michael, Biffl, Walter L., Boermeester, Marja A., Brecher, Stephen M., Cherry-Bukowiec, Jill R., Buyne, Otmar R., Cainzos, Miguel A., Cairns, Kelly A., Camacho-Ortiz, Adrian, Chandy, Sujith J., Che Jusoh, Asri, Chichom-Mefire, Alain, Colijn, Caroline, Corcione, Francesco, Cui, Yunfeng, Curcio, Daniel, Delibegovic, Samir, Demetrashvili, Zaza, De Simone, Belinda, Dhingra, Sameer, Diaz, José J., Di Carlo, Isidoro, Dillip, Angel, Di Saverio, Salomone, Doyle, Michael P., Dorj, Gereltuya, Dogjani, Agron, Dupont, Hervé, Eachempati, Soumitra R., Enani, Mushira Abdulaziz, Egiev, Valery N., Elmangory, Mutasim M., Ferrada, Paula, Fitchett, Joseph R., Fraga, Gustavo P., Guessennd, Nathalie, Giamarellou, Helen, Ghnnam, Wagih, Gkiokas, George, Goldberg, Staphanie R., Gomes, Carlos Augusto, Gomi, Harumi, Guzmán-Blanco, Manuel, Haque, Mainul, Hansen, Sonja, Hecker, Andreas, Heizmann, Wolfgang R., Herzog, Torsten, Hodonou, Adrien Montcho, Hong, Suk-Kyung, Kafka-Ritsch, Reinhold, Kaplan, Lewis J., Kapoor, Garima, Karamarkovic, Aleksandar, Kees, Martin G., Kenig, Jakub, Kiguba, Ronald, Kim, Peter K., Kluger, Yoram, Khokha, Vladimir, Koike, Kaoru, Kok, Kenneth Y. Y., Kong, Victory, Knox, Matthew C., Inaba, Kenji, Isik, Arda, Iskandar, Katia, Ivatury, Rao R., Labbate, Maurizio, Labricciosa, Francesco M., Laterre, Pierre-François, Latifi, Rifat, Lee, Jae Gil, Lee, Young Ran, Leone, Marc, Leppaniemi, Ari, Li, Yousheng, Liang, Stephen Y., Loho, Tonny, Maegele, Marc, Malama, Sydney, Marei, Hany E., Martin-Loeches, Ignacio, Marwah, Sanjay, Massele, Amos, McFarlane, Michael, Melo, Renato Bessa, Negoi, Ionut, Nicolau, David P., Nord, Carl Erik, Ofori-Asenso, Richard, Omari, AbdelKarim H., Ordonez, Carlos A., Ouadii, Mouaqit, Pereira Júnior, Gerson Alves, Piazza, Diego, Pupelis, Guntars, Rawson, Timothy Miles, Rems, Miran, Rizoli, Sandro, Rocha, Claudio, Sakakhushev, Boris, Sanchez-Garcia, Miguel, Sato, Norio, Segovia Lohse, Helmut A., Sganga, Gabriele, Siribumrungwong, Boonying, Shelat, Vishal G., Soreide, Kjetil, Soto, Rodolfo, Talving, Peep, Tilsed, Jonathan V., Timsit, Jean-Francois, Trueba, Gabriel, Trung, Ngo Tat, Ulrych, Jan, van Goor, Harry, Vereczkei, Andras, Vohra, Ravinder S., Wani, Imtiaz, Uhl, Waldemar, Xiao, Yonghong, Yuan, Kuo-Ching, Zachariah, Sanoop K., Zahar, Jean-Ralph, Zakrison, Tanya L., Corcione, Antonio, Melotti, Rita M., Viscoli, Claudio, and Viale, Perluigi
- Abstract
Intra-abdominal infections (IAI) are an important cause of morbidity and are frequently associated with poor prognosis, particularly in high-risk patients. The cornerstones in the management of complicated IAIs are timely effective source control with appropriate antimicrobial therapy. Empiric antimicrobial therapy is important in the management of intra-abdominal infections and must be broad enough to cover all likely organisms because inappropriate initial antimicrobial therapy is associated with poor patient outcomes and the development of bacterial resistance. The overuse of antimicrobials is widely accepted as a major driver of some emerging infections (such as C. difficile), the selection of resistant pathogens in individual patients, and for the continued development of antimicrobial resistance globally. The growing emergence of multi-drug resistant organisms and the limited development of new agents available to counteract them have caused an impending crisis with alarming implications, especially with regards to Gram-negative bacteria. An international task force from 79 different countries has joined this project by sharing a document on the rational use of antimicrobials for patients with IAIs. The project has been termed AGORA (Antimicrobials: A Global Alliance for Optimizing their Rational Use in Intra-Abdominal Infections). The authors hope that AGORA, involving many of the world's leading experts, can actively raise awareness in health workers and can improve prescribing behavior in treating IAIs.
- Published
- 2016
- Full Text
- View/download PDF
13. The role of erythropoietin-loaded hydrogel versus adipose derived stem cell secretome in the regeneration of tongue defects.
- Author
-
El-Qashty R, Youssef J, and Hany E
- Subjects
- Animals, Male, Rats, Macrophages drug effects, Neovascularization, Physiologic drug effects, Rats, Wistar, Wound Healing drug effects, Adipose Tissue metabolism, Erythropoietin pharmacology, Erythropoietin therapeutic use, Hydrogels, Regeneration drug effects, Secretome, Tongue pathology
- Abstract
Background: Tongue defects have several etiologies and significantly affect the quality of life. This study was conducted to compare the regenerative potential of erythropoietin (EPO)-loaded hydrogel and adipose derived stem cell (ADSC) secretome on tongue dorsum defects focusing on the role of anti-inflammatory M2 macrophage phenotype., Methods: Rats were subjected to induction of mechanical circular defects on the dorsal surface of the tongue, then divided into three groups; Group I (control): received 0.1 ml phosphate buffered saline, Group II (EPO): received 5000 U/kg EPO-hydrogel, and Group III (ADSC-Secretome): received 0.1 ml ADSC-Secretome. Treatments were injected circumferentially around wound margins after induction. Seven and fourteen days after treatment, specimens were obtained and processed for histological and immunohistochemical staining followed by the relevant histomorphometric and statistical analyses., Results: Seven days after treatment, groups II and III presented defects with some epithelial regeneration at the lateral margins, while the center of the defect showed granulation tissue with much inflammatory cells. The base of the defects showed some muscle fibers and new blood vessels, however group III showed more enhanced neovascularization. Fourteen days after therapeutic intervention, group II defects were completely covered with epithelium showing a thin keratin layer with regular rete pegs interdigitating with the underlying connective tissue papillae, but tongue papillae were not restored. Group III expressed much better healing with developing filiform papillae. The connective tissue showed more vascularity and well-arranged muscle bundles. Both treated groups showed a significant decrease in defect depth and significant increase in anti-inflammatory macrophages compared to the control group at both time intervals, however there was no significant difference between the two treated groups., Conclusion: Both treatments showed promising and comparable results in the treatment of tongue defects reducing inflammation and restoring tongue histological architecture with significant upregulation of M2 macrophage., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
14. Photobiostimulation conjugated with stem cells or their secretome for temporomandibular joint arthritis in a rat model.
- Author
-
El-Qashty R, Elkashty OA, and Hany E
- Subjects
- Rats, Animals, Mice, Tumor Necrosis Factor-alpha metabolism, Secretome, Temporomandibular Joint, Stem Cells metabolism, Proteoglycans, Arthritis pathology, Temporomandibular Joint Disorders therapy, Temporomandibular Joint Disorders pathology
- Abstract
Background: Temporomandibular joint (TMJ) arthritis is a debilitating, challenging condition and different methods have been implicated for its treatment. This study aimed to test the therapeutic potentials of low-level laser therapy (LLLT) associated with adipose derived stem cells (ADSC) or their derived secretome on a murine model induced arthritis., Methods: Forty eight rats were divided into four groups where group I was the sham control, the rest of animals were subjected to arthritis induction using complete Freund's adjuvant, then divided as follows: group II received phosphate buffered saline (PBS) intraarticular injection and irradiation of 0 j/cm2, group III received ADSCs derived secretome and irradiation of 38 j/cm2, and group IV received ADSCs and irradiation of 38 j/cm2 as well. One and three weeks after treatment, animals were euthanized, and paraffin blocks were processed for histological assessment by hematoxylin and eosin stain with histomorphometrical analysis. Histochemical evaluation of joint proteoglycan content was performed through toluidine blue stain, and immunohistochemical staining by the proinflammatory marker tumor necrosis factor-α (TNF-α) was performed followed by the relevant statistical tests., Results: The arthritis group showed histological signs of joint injury including cartilage atrophy, articular disc fibrosis, irregular osteochondral interface, and condylar bone resorption together with high inflammatory reaction and defective proteoglycan content. In contrast, the treated groups III and IV showed much restoration of the joint structure with normal cartilage and disc thickness. The inflammation process was significantly suppressed especially after three weeks as confirmed by the significant reduction in TNF-α positive immunostaining compared to the arthritic group, and the cartilage proteoglycan content also showed significant increase relative to the arthritic group. However, no significant difference between the results of the two treated groups was detected., Conclusion: LLLT conjugated with ADSCs or ADSCs derived secretome can efficiently enhance the healing of arthritic TMJs. Stem cell secretome can be applied as a safe, potent therapy. However, further investigations are required to unravel its mechanism of action and pave its way as a safe, novel, cell free therapy., (© 2023. BioMed Central Ltd., part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.